Target for Treatment

From the Clinical Practice Guidelines for the Management of Dyslipidemia by the Philippine Heart Association
This guideline starts below.

Target for Treatment

The role of LDL in atherogenesis and elevated LDL in CVD is well established. Prestatin and statin trials in which LDL reduction was the major lipid response resulting in improvements in coronary lesions and clinical outcomes, further validate the role of LDL as a target of therapy. In near-optimal treatment, significant risk reductions are observed with approximate 30% to 40% LDL reduction from baseline. This may be translated to an approximate LDL reduction of 38 mg/dL (1 mmol/L).

Furthermore, studies that evaluated intensive statin therapy, such as the PROVE-IT and the Treating to New Targets (TNT) trials, showed additional CV benefits, together with slight increases in the frequency of serious adverse events when LDL is decreased to less than 77 mg/dL through intensive statin therapy (e.g., atorvastatin 80 mg/day instead of 10 mg/day). Therefore, a 30% to 40% LDL reduction from baseline or LDL < 77 mg/dL are suitable treatment goals.